Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 19, 2023 | SVP Global Operations and R&D | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,789 | -- | 28,986 | |
| Jul 17, 2019 | SVP and GM of Oncology | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,790 | -- | 10,790 | |
| Nov 21, 2017 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 10,873 | $17.42 | 58,703 | |
| Aug 12, 2021 | EVP and CFO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,946 | -- | 79,254 | |
| Feb 01, 2021 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,000 | -- | 11,000 | |
| Jul 21, 2021 | SVP Global Operations and R&D | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,026 | -- | 11,026 | |
| Jun 06, 2005 | Director | Form 4 | Open market or private sale of non-derivative or derivative security | 11,084 | $21.24 | 506,039 | |
| Jul 18, 2018 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,276 | -- | 11,276 | |
| Jul 19, 2023 | Director, President and CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 11,379 | $8.92 | 549,259 | |
| Jul 19, 2023 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,384 | -- | 48,263 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.